aTyr Pharma Past Earnings Performance
Past criteria checks 0/6
aTyr Pharma's earnings have been declining at an average annual rate of -23%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
-23.0%
Earnings growth rate
46.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 3.7% |
Return on equity | -71.1% |
Net Margin | -9,846.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan
Jan 14ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study
Jan 04aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study
Dec 21aTyr Pharma (LIFE) Investor Presentation - Slideshow
Oct 31Revenue & Expenses Breakdown
How aTyr Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1 | -58 | 13 | 0 |
31 Mar 24 | 1 | -54 | 13 | 0 |
31 Dec 23 | 0 | -50 | 13 | 0 |
30 Sep 23 | 11 | -43 | 13 | 0 |
30 Jun 23 | 10 | -45 | 14 | 0 |
31 Mar 23 | 10 | -45 | 14 | 0 |
31 Dec 22 | 10 | -45 | 14 | 0 |
30 Sep 22 | 0 | -46 | 13 | 0 |
30 Jun 22 | 0 | -41 | 12 | 0 |
31 Mar 22 | 0 | -39 | 12 | 0 |
31 Dec 21 | 0 | -34 | 11 | 0 |
30 Sep 21 | 2 | -30 | 10 | 0 |
30 Jun 21 | 2 | -29 | 10 | 0 |
31 Mar 21 | 2 | -25 | 9 | 0 |
31 Dec 20 | 10 | -16 | 9 | 0 |
30 Sep 20 | 9 | -17 | 9 | 0 |
30 Jun 20 | 9 | -16 | 9 | 0 |
31 Mar 20 | 8 | -16 | 9 | 0 |
31 Dec 19 | 0 | -24 | 9 | 0 |
30 Sep 19 | 0 | -24 | 9 | 0 |
30 Jun 19 | 0 | -25 | 10 | 0 |
31 Mar 19 | 0 | -30 | 11 | -6 |
31 Dec 18 | 0 | -35 | 12 | 0 |
30 Sep 18 | 0 | -40 | 16 | 5 |
30 Jun 18 | 0 | -44 | 17 | 12 |
31 Mar 18 | 0 | -45 | 17 | 27 |
31 Dec 17 | 0 | -48 | 17 | 0 |
30 Sep 17 | 0 | -49 | 15 | 34 |
30 Jun 17 | 0 | -52 | 14 | 37 |
31 Mar 17 | 0 | -55 | 15 | 40 |
31 Dec 16 | 0 | -58 | 15 | 43 |
30 Sep 16 | 0 | -62 | 16 | 46 |
30 Jun 16 | 0 | -59 | 16 | 44 |
31 Mar 16 | 0 | -55 | 15 | 40 |
31 Dec 15 | 0 | -48 | 13 | 33 |
30 Sep 15 | 0 | -38 | 11 | 25 |
30 Jun 15 | 0 | -33 | 9 | 21 |
31 Mar 15 | 0 | -28 | 8 | 18 |
31 Dec 14 | 0 | -25 | 7 | 17 |
30 Sep 14 | 0 | -24 | 6 | 17 |
Quality Earnings: ATYR is currently unprofitable.
Growing Profit Margin: ATYR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATYR is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare ATYR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATYR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ATYR has a negative Return on Equity (-71.1%), as it is currently unprofitable.